Upon administration, the CD44-T-PNPs ester backbone was hydrolyzed into non-toxic products with gradual releasing of the CFM-4.16 molecules and S0456 in the tumor site with low off-target distribution, which pave its application as a promising tool for the theranostic purpose. The gene discussed is CD44; the disease is neoplasm.